[Is there a role for calcium antagonists when beta-adrenergic blockade therapy is contraindicated in post-myocardial infarction?].

Abstract

The purpose of this paper is to examine the eventual benefits of treatment with calcium channel blockers in post-myocardial infarction, through an overview of main placebo-controlled trials that have been conducted to test this therapeutic in acute coronary syndromes. It appears obvious that the vast majority of these trials was conducted in the pre-reperfusion era and failed to demonstrate a reduction in mortality. To conclude, the superiority of a therapy with calcium antagonists over a placebo in the management of post-myocardial infarction remains unknown. In contrast, adverse effects associated with the prescription of calcium antagonists are well known.

• Authors: Pierre-Vladimir Ennezat, Jean-Luc Auffray, Julie Darchis, Maxime Rousselle, Xavier Gonin, Jean-Marc Aubert, Jean-Jacques Bauchart, Christophe Bauters, Eric Van Belle, Philippe Asseman
• Journal: Therapie (Therapie) 2006 May-Jun Vol. 61 Issue 3 Pg. 191-4 ISSN: 0040-5957 [Print] France
• Vernacular Title: Quelle est la place des inhibiteurs calciques lorsque les bêta-bloquants sont contre-indiqués dans le traitement du post-infarctus du myocarde?
• PMID: 16989118 (Publication Type: Journal Article, Review)

Chemical References

• Adrenergic beta-Antagonists
• Calcium Channel Blockers
• Verapamil
• Diltiazem
• Nifedipine

Topics

• Adrenergic beta-Antagonists
• Calcium Channel Blockers (therapeutic use)
• Contraindications
• Diltiazem (therapeutic use)
• Humans
• Long QT Syndrome (drug therapy)
• Myocardial Infarction (drug therapy)
• Nifedipine (therapeutic use)
• Verapamil (therapeutic use)